Biosimilars Forum Welcomes Amneal as Newest Member
Amneal joins the leading biosimilar industry coalition in its efforts to increase access to lower-cost biosimilars for patients
The Biosimilars Forum has announced Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) as its newest member. Amneal joins the Forum as it leads the biosimilar industry’s efforts to promote safe, effective and lower-cost biosimilars during a watershed moment for the industry.
“We are thrilled to join the Biosimilars Forum to work together to increase biosimilar uptake and help make more life-saving treatments available to patients who need them,” Chirag Patel, President and Co-Chief Executive Officer at Amneal. “Amneal and the Biosimilars Forum share a commitment to ensuring biosimilars are available to patients and that the cost-savings potential of biosimilars become a reality.”
Biosimilars have the potential to save billions of dollars in U.S. health care spending, if — and only if — they have equitable access to formularies, allowing free-market competition to lower prescription drug costs. The Biosimilars Forum works to advance biosimilars in the United States with the goals of expanding access and availability and improving healthcare outcomes.
“The Forum’s Board of Directors and I are honored to welcome Amneal to the Biosimilars Forum at the most critical time for the future of the industry,” said Juliana M. Reed, Executive Director of the Biosimilars Forum. “The Biosimilars Forum supports a competitive market environment that enables safe, effective and lower-cost biosimilars and innovation to thrive.”
For more information on the Biosimilars Forum’s work to increase access to lower-cost biosimilars, visit biosimilarsforum.org.
About the Biosimilars Forum
The Biosimilars Forum is a nonprofit organization working to advance biosimilars in the United States with the goals of expanding access and availability and improving healthcare outcomes. Since its inception, the Forum has worked to expand the uptake of biosimilars throughout the healthcare system through policies that will increase access for patients and lower costs through increased competition. Forum members represent companies with the most significant U.S. biosimilars development portfolios.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.